Mercadante Sebastiano
Main Regional Center for Pain Relief and Supportive/Palliative Care, La Maddalena Cancer Center, Via San Lorenzo 312, 90100, Palermo, Italy.
Pain Ther. 2023 Jun;12(3):645-654. doi: 10.1007/s40122-023-00507-z. Epub 2023 Apr 13.
This critical review assessed the advantages of invasive procedures that were recently included in systematic reviews, to evaluate whether the definition of refractory pain condition was correctly followed to select patients for invasive interventions and to analyze how data were positively interpreted. A total of 21 studies were selected for the purpose of this review. Three were randomized controlled studies, ten were prospective studies, and eight were retrospective studies. Analysis of these studies showed evident lack of proper assessment before implantation for different reasons. These included an optimistic interpretation regarding the outcomes, poor consideration of complications, and inclusion of patients with short survival. Moreover, the indication of intrathecal therapy as a condition in which a patient has failed to respond to multiple therapies provided by a pain or palliative care physician or at sufficient doses for adequate durations, as suggested by a recent research group, has been disregarded. Regretfully, this can discourage the use of intrathecal therapy in patients who are unresponsive to multiple opioid strategies subtrahend a potent means to be used in a very selective population.
这篇批判性综述评估了近期纳入系统评价的侵入性操作的优势,以评估在选择患者进行侵入性干预时是否正确遵循了难治性疼痛状况的定义,并分析数据是如何得到积极解读的。为了本次综述,共选取了21项研究。其中三项为随机对照研究,十项为前瞻性研究,八项为回顾性研究。对这些研究的分析表明,由于不同原因,植入前明显缺乏适当的评估。这些原因包括对结果的乐观解读、对并发症的考虑不足以及纳入生存期短的患者。此外,正如最近一个研究小组所建议的,鞘内治疗的指征是患者对疼痛或姑息治疗医生提供的多种治疗或足够剂量且足够疗程的治疗无反应,但这一指征被忽视了。遗憾的是,这可能会阻碍在对多种阿片类药物策略无反应的患者中使用鞘内治疗,而鞘内治疗是一种仅适用于非常特定人群的有效手段。